Strikingly, signaling downstream of mutant KRAS in pancreatic cancers leads to mitochondrial fragmentation and increased activation of Drp1, processes that are required for KRAS-driven tumor growth in vivo. The gene discussed is DNM1L; the disease is neoplasm.